<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667143</url>
  </required_header>
  <id_info>
    <org_study_id>SHR3824-SP2086-MET-301</org_study_id>
    <nct_id>NCT04667143</nct_id>
  </id_info>
  <brief_title>Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein Added to Metformin Compared to Retagliptin or Henagliflozein in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to&#xD;
      evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin&#xD;
      compared to Retagliptin or Henagliflozein in combination with Metformin in Subjects with Type&#xD;
      2 Diabetes who have Inadequate Glycemic Control on Metformin Alone&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in HbA1c at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>• To compare the mean change from baseline in HbA1c achieved with concurrent addition of Retagliptin Plus Henagliflozein to metformin vs the addition of Retagliptin or Henagliflozein to metformin after 24 weeks of double-blind treatment.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retagliptin, Henagliflozein, metformin XR</intervention_name>
    <description>Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR</description>
    <arm_group_label>Retagliptin 100 mg, Henagliflozein 10 mg, plus metformin XR</arm_group_label>
    <arm_group_label>Retagliptin 100 mg, Henagliflozein 5 mg, plus metformin XR</arm_group_label>
    <arm_group_label>Retagliptin 100 mg, Henagliflozein placebo, plus metformin XR</arm_group_label>
    <arm_group_label>Retagliptin placebo, Henagliflozein 10 mg, plus metformin XR</arm_group_label>
    <arm_group_label>Retagliptin placebo, Henagliflozein 5 mg, plus metformin XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, 18-75 years old (both inclusive) at time of screening visit;&#xD;
&#xD;
          2. Subjects with T2DM with inadequate glycemic control defined as central laboratory&#xD;
             HbA1c ≥ 7.5 and ≤ 10.5 % at the screening visit;&#xD;
&#xD;
          3. FPG ≤ 15mmol/L at the screening visit;&#xD;
&#xD;
          4. Stable metformin therapy for at least 8 weeks prior to screening at a dose ≥ 1500 mg&#xD;
             per day;&#xD;
&#xD;
          5. 19.0&lt;BMI ≤ 40.0 kg/m2 at the screening visit;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Moderate or severe impairment of renal function [defined as eGFR&lt;60mL/min/1.73 m2&#xD;
             (estimated by MDRD);&#xD;
&#xD;
          2. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg and/or&#xD;
             diastolic blood pressure (DBP) ≥ 100 mmHg;&#xD;
&#xD;
          3. Cardiovascular diseases within 6 months of the screening visit;&#xD;
&#xD;
          4. ALT and/or AST &gt; 1.5 x ULN and or Total Bilirubin &gt; 1.2 x ULN;&#xD;
&#xD;
          5. Hemoglobin ≤ 100 g/L;&#xD;
&#xD;
          6. CK (creatine kinase) and CK-MB &gt; 3 x ULN;&#xD;
&#xD;
          7. Malignancy within 5 years of the screening visit (with the exception of treated basal&#xD;
             cell or treated squamous cell carcinoma);&#xD;
&#xD;
          8. Administration of any antihyperglycemic therapy, other than metformin,within 2 months&#xD;
             prior to screening;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

